Last reviewed · How we verify
ISM5411
At a glance
| Generic name | ISM5411 |
|---|---|
| Sponsor | InSilico Medicine Hong Kong Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study Evaluating ISM5411 Administered Orally to Subjects With Active Ulcerative Colitis (BETHESDA) (PHASE2)
- Study Evaluating ISM5411 Administered Orally to Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ISM5411 CI brief — competitive landscape report
- ISM5411 updates RSS · CI watch RSS
- InSilico Medicine Hong Kong Limited portfolio CI